Evidence map›Paper›PMID 35296558›Full record

ArticleJournal for immunotherapy of cancer2022

Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.

Jacob P van Vloten, Kathy Matuszewska, Mark A A Minow, Jessica A Minott, Lisa A Santry, Madison Pereira, Ashley A Stegelmeier, Thomas M McAusland, Elaine M Klafuric, Khalil Karimi and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Jacob P van VlotenDepartment of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Kathy MatuszewskaDepartment of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.
Mark A A MinowMolecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
Jessica A MinottDepartment of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Lisa A SantryDepartment of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Madison PereiraDepartment of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.
Ashley A Stegelmeier *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Thomas M McAusland *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Elaine M Klafuric *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Khalil KarimiDepartment of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Joseph ColasantiDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
D Grant McFaddenBiodesign Institute, Arizona State University, Tempe, Arizona, USA.
James J PetrikDepartment of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.
Byram W BridleDepartment of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Sarah K WoottonDepartment of Pathobiology, University of Guelph, Guelph, Ontario, Canada kwootton@uoguelph.ca.ORCID 0000-0002-5985-2406
University of Guelph · CAArizona State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel therapies are needed to improve outcomes for women diagnosed with ovarian cancer. Oncolytic viruses are multifunctional immunotherapeutic biologics that preferentially infect cancer cells and stimulate inflammation with the potential to generate antitumor immunity. Herein we describe

methodsThe immunotherapeutic potential of OrfV was tested in the ID8 orthotopic mouse model of end-stage epithelial ovarian carcinoma. Immune cell profiling, impact on secondary lesion development and survival were evaluated in OrfV-treated mice as well as in Batf3 knockout, mice depleted of specific immune cell subsets and in mice where the primary tumor was removed. Finally, we interrogated gene expression datasets from primary human ovarian tumors from the International Cancer Genome Consortium database to determine whether the interplay we observed between natural killer (NK) cells, classical type 1 dendritic cells (cDC1s) and T cells exists and influences outcomes in human ovarian cancer.

resultsOrfV was an effective monotherapy in a murine model of advanced-stage epithelial ovarian cancer. OrfV intervention relied on NK cells, which when depleted abrogated antitumor CD8

conclusionsThe data herein support the translational potential of OrfV as an NK stimulating immunotherapeutic for the treatment of advanced-stage ovarian cancer.

Indexed as

Oncolytic VirotherapyOncolytic VirusesOrf virusOvarian NeoplasmsAnimalsCarcinoma, Ovarian EpithelialCell Line, TumorDisease Models, AnimalFemaleHumansKiller Cells, NaturalLicensureMiceSheepkiller cells, naturallymphocytes, tumor-infiltratingoncolytic virotherapyoncolytic virusestumor microenvironment

Identifiers

PMID35296558
PMCPMC8928368
OpenAlexW4220720824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.